By
BERLIN: Novartis on Thursday posted a slightly more optimistic full-year earnings forecast, citing the strong growth of drugs such as breast cancer drug Kisqali during the second quarter.
The Swiss drugmaker said it now expects core operating income to grow in the low teens, from the low double-digits cited previously.